Skywork ( unveiled Skywork Super Agents to the global market. This cutting-edge product leverages AI agent architecture and ...

Verismo Therapeutics, a clinical-stage CAR T company pioneering the KIR-CAR platform, today provided additional details on ...

Presenter: Eunice S. Wang, M.D. A post-hoc analysis of the pivotal cohort from the Phase 1/2 study evaluated outcomes in patients with R/R mIDH1 AML who received olutasidenib after either 1-2 or ...

Title: Efficacy and Safety of Pralsetinib in Patients with Advanced RET-fusion-positive NSCLC: Final Data from the Phase 1/2 ARROW Study Presenter: Eunice S. Wang, M.D. A post-hoc analysis of ...

Discover how poorly made PowerPoint presentations waste millions in productivity, drain team focus, and increase business ...

Poster Presentation Details: Title: Phase 1/2 Duravelo-1 study: Preliminary results of Nectin-4-targeting zelenectide pevedotin (BT8009) plus pembrolizumab in previously untreated, cisplatin ...

Presentations are big business. When movie stars such as Leonard DiCaprio and Matthew McConaughey get up to a million dollars ...

Final data from the GAVRETO ® (pralsetinib) Phase 1/2 ARROW study in RET fusion-positive NSCLC and other solid tumors ...

Rigel's poster presentations will include data for GAVRETO ® (pralsetinib) for the treatment of metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC ...

today announced the poster presentation of two abstracts at the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting, taking place May 30-June 3 in Chicago.

Presenter: Eunice S. Wang, M.D. A post-hoc analysis of the pivotal cohort from the Phase 1/2 study evaluated outcomes in patients with R/R mIDH1 AML who received olutasidenib after either 1-2 or ≥3 ...